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ABSTRACT
Background: Postoperative abdominal and shoulder
pain are the most common complaints after elective lapa-
roscopic cholecystectomy. Postoperative pain is multifac-
torial in origin, and therefore multimodal therapy may be
needed to optimize pain relief.
Methods: We conducted a double-blind study where
patients were randomly allocated to 1 of 5 groups of 20
patients each. Statistical significance was considered
P0.05. Group 1 received 40mL bupivacaine 0.25% intra-
peritoneal spray. Group 2 received 40 mL bupivacaine
0.25% intraperitoneal spray mixed with 200 mg ketopro-
fen. Group 3 received 40 mL bupivacaine 0.25% intraperi-
toneal spray and intravenous 200 mg ketoprofen. Group 4
received 200mg ketoprofen intravenously. Group 5 was
the control group.
Results: Demographic data were similar in the 5 groups.
As compared with the control group, group 1 had signif-
icantly lower abdominal pain scores at 6 hours; group 2 at
0, 1, 2, and 6 hours; group 3 at 0, 1, 2, 6, 12, and 24 hours;
and group 4 at 2 hours. Group 1 had significantly lower
shoulder pain scores at 1 and 6 hours; group 2 at 0 and 6
hours; and groups 3 and 4 at 0, 1, and 6 hours. The
number of patients requiring postoperative rescue anal-
gesics and the incidence of postoperative vomiting were
significantly lower in group 3 only.
Conclusions: A multimodal approach to pain manage-
ment following elective laparoscopic cholecystectomy is
best achieved with a combination of 40 mL bupivacaine
0.25% intraperitoneal spray and 200 mg intravenous ke-
toprofen, achieving the least incidence of postoperative
vomiting.
Key Words: Laparoscopic cholecystectomy, Postopera-
tive pain, Intraperitoneal bupivacaine, Intravenous keto-
profen.
INTRODUCTION
The laparoscopic approach to cholecystectomy has been
proven to reduce postoperative pain significantly and
shorten the recovery period, therefore, reducing discharge
time from 1 day to 3 days to same day discharge with an
earlier return to a normal life.1,2 Nonetheless, studies have
shown that the first 24 hours to 48 hours after surgery are
associated with moderate abdominal and shoulder pain in
35% to 63% of patients. Early postoperative pain is the
most common complaint after elective laparoscopic cho-
lecystectomy; pain intensity peaks during the first postop-
erative hours and usually declines over the following 2
days to 3 days.3,4
Numerous clinical studies have investigated the use of
regional local anesthetics, in combination with other mo-
dalities for pain relief following laparoscopic cholecystec-
tomy to avoid the adverse effects of opioids, which may
delay recovery and hospital discharge.5 Thirteen con-
trolled studies have investigated the analgesic effects of
bupivacaine administered in the right subdiaphragmatic
or gallbladder region; only 7 of the 13 trials found that the
overall pain scores were significantly reduced as com-
pared with those of the control patients.6
Although nonsteroidal anti-inflammatory drugs provide
morphine-sparing effects, they do not appear to provide,
on their own, sufficiently reliable postoperative analgesia
for laparoscopic surgery.5 Salman et al7 failed to observe
an improvement in analgesia after laparoscopic surgery
with the use of tenoxicam 20 mg intravenously. However,
Elhakim et al8 reported that a combination of tenoxicam
20 mg and lidocaine 1%, administered intraperitoneally
under the right diaphragm and on the gallbladder bed
after laparoscopic cholecystectomy, provided superior an-
algesia for movement and a faster return of bowel func-
tion as compared with intraperitoneal lidocaine and intra-
venous tenoxicam or placebo.
In view of these conflicting results, we designed in pa-
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SCIENTIFIC PAPERtients undergoing elective laparoscopic cholecystectomy
this double-blind, prospective, placebo-controlled study
to compare the degree of postoperative pain relief, nau-
sea, and vomiting following intraperitoneal spray of bu-
pivacaine alone or intravenous ketoprofen alone, versus
the multimodal combination of intraperitoneal bupiva-
caine with intraperitoneal or intravenous ketoprofen.
METHODS
After obtaining institutional approval for the protocol and
informed consent, 100 patients, ASA I-II aged 20 years to
60 years, scheduled for elective laparoscopic cholecystec-
tomy without intraoperative cholangiography, were en-
rolled in the study. The criteria for exclusion were chronic
pain diseases other than gallstone disease, and use of
opioids, tranquilizers, steroids, nonsteroidal anti-inflam-
matory drugs, or alcohol. Also, exclusion criteria included
amide local anesthetic allergy and contraindications to
nonsteroidal anti-inflammatory drugs (allergy, peptic ul-
cer disease, gastroesophageal reflux disease, renal insuf-
ficiency, coagulopathy). In addition, patients with acute
cholecystitis, conversion to an open cholecystectomy,
postoperative complications that increased postoperative
pain, and those whose pain evaluation was judged unre-
liable because of neurologic disease were excluded. Fi-
nally, patients who demonstrated the intraoperative need
for more than 2 g/kg fentanyl, as evidenced by an
increase of more than 20% of mean arterial blood pressure
or heart rate that is not controlled by increasing sevoflu-
rane concentration for 5 minutes, were also excluded.
All patients were premedicated 1 hour before surgery with
diazepam 5 mg orally, glycopyrrolate 0.2 mg intramuscu-
larly, and ranitidine 50 mg intravenously. Intraoperative
monitoring included continuous electrocardiogram, heart
rate, Spo2, end-tidal CO2, sevoflurane concentration, in-
termittent noninvasive blood pressure, and neuromuscu-
lar block. General anesthesia was induced intravenously
with propofol 2.0 mg/kg, fentanyl 2 g/kg, and rocuro-
nium 0.6 mg/kg, to be followed by orotracheal intubation.
Anesthesia was maintained with sevoflurane 1.5% to 2.5%
in oxygen/air mixture (1/2). Increments of 10 mg of rocu-
ronium were administered repetitively to maintain a train-
of-4 ratio (T4/T1)0.5. During laparoscopy, carbon diox-
ide was insufflated intraperitoneally to maintain an
intraabdominal pressure between 10 mm Hg to 15 mm
Hg. Minute ventilation volume was adjusted to keep end-
tidal PCO2 at 35 mm Hg to 40 mm Hg. At the end of
surgery, the CO2 was carefully evacuated by manual com-
pression of the abdomen with open trocars. The residual
neuromuscular blockade was reversed with a mixture of
neostigmine 0.05 mg/kg
-1 and glycopyrrolate 0.01 mg/
kg
-1.
Patients were randomly allocated to 1 of 5 groups, each of
which consisted of 20 patients. Group 1 received a 40 mL
solution of bupivacaine 0.25% intraperitoneal spray alone
and 40 mL of normal saline intravenously. Group 2 re-
ceived a 40 mL solution of bupivacaine 0.25% intraperito-
neal spray mixed with 200 mg ketoprofen and 40 mL of
normal saline intravenously. Group 3 received a 40 mL
solution of bupivacaine 0.25% intraperitoneal spray alone
and intravenous ketoprofen 200 mg diluted in 40 mL of
normal saline intravenously. Group 4 received normal
saline 40 mL intraperitoneally and 200 mg intravenous
ketoprofen diluted in 40 mL of normal saline. Group 5
(control) received normal saline 40 mL intraperitoneally
and 40 mL of normal saline intravenously.
A surgical scrub nurse who had no further involvement in
the study prepared the solutions administered intraperito-
neally to the study patients. An anesthesiologist not par-
ticipating in the study administered 40 mL of a blinded
solution (ketoprofen or saline) intravenously 30 minutes
before the end of the operation to all patients. At the end
of surgery and before evacuating the pneumoperitoneum,
the surgeon sprayed 40 mL of a blinded solution (bupiv-
acaine  ketoprofen or saline) intraperitoneally in a stan-
dardized manner to the subdiaphragmatic space and gall-
bladder area. The anesthesiologists and nurses in the
postanesthesia care unit and in the ward were unaware of
the treatment to which each patient had been random-
ized. Postoperative abdominal and shoulder pain were
evaluated in terms of intensity and location upon arrival to
the recovery room, and at 1, 2, 6, 12, and 24 hours
postoperatively. Pain scoring was evaluated by the same
anesthesiologist who was blinded to all groups by a visual
analogue score (VAS) of 0 to 10 (0no pain, 10unen-
durable pain), which was explained to the patients during
the preanesthesia visit. In case of a pain score 5, a
ketoprofen 100mg suppository was given and repeated
every 6 hours for the first 24 hours if needed. The number
of patients requiring rescue analgesics was recorded. Post-
operative nausea and vomiting (PONV) was rated by the
same anesthesiologist on a 3-point scale (0no PONV,
1Mild nausea, 2Severe nausea, 3Vomiting) upon ar-
rival to the recovery room, and at 1, 2, 6, 12, and 24 hours
postoperatively. If PONV scale was 2 or more, ondanse-
tron 4mg was given intravenously and repeated as needed
every 6 hours for the first 24 hours. The incidence of
postoperative vomiting (PONV scale 3) was recorded.
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All data are reported as mean  SD, except for the per-
centage of patients who needed postoperative rescue an-
algesics, and the incidence of postoperative vomiting.
Postoperative abdominal and shoulder pain scores were
compared with the analysis of variance with the Bonfer-
roni post hoc test. The percentage of patients who needed
rescue analgesics and the incidence of postoperative vom-
iting were compared by using the chi-square test. Statis-
tical significance was considered at P0.05. A 50% reduc-
tion in the incidence of pain was used in computing the
power analysis. Also, a type I error of 5% as well as a type
II error of 20% were used in the power analysis. The result
of the power analysis indicated that a minimum of 20
patients was needed in each group.
RESULTS
Demographic Data
The demographic data are shown in Table 1. No signifi-
cant difference was found between the 5 groups in terms
of sex distribution, mean patient body weight and age, or
ASA status and duration of surgery.
Abdominal Pain
Postoperative abdominal pain scores (mean  SD) are
shown in Figure 1.
Group 1 had significantly lower pain scores than did the
control group at 6 hours only. Group 2 had significantly
lower pain scores than did the control group at 0, 1, 2, and
6 hours. Group 3 had significantly lower pain scores than
did the control group at 0, 1, 2, 6, 12, and 24 hours. Group
4 had significantly lower pain scores than did the control
group at 2 hours only.
Shoulder Pain
Postoperative shoulder pain scores (mean  SD) are
shown in Figure 2.
Group 1 had significantly lower pain scores than did the
control group at 1 and 6 hours. Group 2 had significantly
lower pain scores than did the control group at 0 and 6
hours. Groups 3 and 4 had significantly lower pain scores
than did the control group at 0, 1, and 6 hours.
Postoperative Rescue Analgesics
The percentage of patients requiring postoperative rescue
analgesics was significantly less in group 3 only, as com-
pared with analgesic needs in the control group (Table 2).
Postoperative Vomiting
The incidence of postoperative vomiting was significantly
less in group 3 only as compared with vomiting in the
control group (Table 3).
DISCUSSION
Postoperative pain and nausea are the most common
complications of laparoscopic surgery, including chole-
Table 1.
Patient Characteristics and Surgical Data*
Variable Group 1
n20
Group 2
n20
Group 3
n20
Group 4
n20
Group 5
n20
Age (year) 4815 4720 4618 46.612 47.217
Weight (Kg) 7210 7312 72.514 7415 7211
ASA I/II 10/10 9/11 10/10 11/9 9/11
Sex (male/female) 9/11 9/11 9/11 9/11 9/11
Duration of surgery (min) 10019 9822 10116 10318 9920
*Data are expressed as meanSD and numbers. No significant differences between groups.
Figure 1. Mean and standard deviation of the abdominal pain
scores in the different groups over time.
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and discharge times and contribute to unanticipated ad-
mission after ambulatory surgery. Pain also contributes to
postoperative nausea and vomiting. Thus, the establish-
ment of laparoscopic cholecystectomy as an outpatient
procedure has accentuated the clinical importance of re-
ducing early postoperative pain and nausea.10 Improved
postoperative pain management using opioid-sparing reg-
imens may facilitate a high success rate of outpatient
laparoscopic cholecystectomy.11
Early pain after laparoscopic cholecystectomy is multifac-
torial and complex. It includes different pain components
due to different pain mechanisms: Abdominal wall pene-
tration by trocars produces somatic pain; rapid distension
of the peritoneum by CO2 insufflation results in tearing of
blood vessels, traction of nerves, and release of inflam-
matory mediators producing visceral pain; inflammation
or local irritation around the gallbladder bed, liver, dia-
phragm or peritoneum, or both, secondary to gallbladder
removal and abdominal muscle distension add to tissue
injury and produce visceral pain. Shoulder pain results
from peritoneal insufflation especially when an exagger-
ated Trendelenburg position is used.12
Because postoperative pain following laparoscopic cho-
lecystectomy is multifactorial, multimodal therapy may be
necessary to optimize pain relief. The present report
shows that the best multimodal therapy that significantly
decreases both abdominal and shoulder pain over the first
24 hours postoperatively, as compared with the control
group, is a combination of 40 mL of bupivacaine 0.25%
(100 mg) intraperitoneal spray and intravenous ketopro-
fen 200 mg. Furthermore, this combination has proven
effective in decreasing the number of patients who
needed rescue analgesics as well as the incidence of
postoperative vomiting, as compared with that in the
control group.
Bupivacaine is an amide-type local anesthetic that is ca-
pable of producing prolonged analgesia. The recom-
mended dose for infiltration is a maximum of 2 mg/kg.
Narchi et al13 showed that intraperitoneal instillation of
100 mg of bupivacaine did not result in toxic plasma
concentrations. The absence of toxicity was confirmed by
Deans et al14 who determined plasma concentrations after
instillation of 1.5 mg/kg bupivacaine in the preperitoneal
space during hernia repair.
In our study, intraperitoneal bupivacaine alone reduced
postoperative shoulder pain significantly at 1 hour and 6
hours, and abdominal pain at 6 hours only. However, no
significant difference occurred in the number of patients
who needed rescue analgesics and in the incidence of
postoperative vomiting as compared with that in the con-
trol group.
Because NSAIDs have analgesic properties comparable to
properties of opioid compounds without opioid-related
side-effects, these drugs are often administered as adju-
vants during and after surgery.15 A systematic review of
published, randomized, controlled trials16 found no sig-
nificant differences in the analgesic effects between dif-
ferent NSAIDs, but found differences in toxicity with in-
creasing doses. Because no documented evidence exists
of the superiority of any particular NSAID for periopera-
tive use, the choice of NSAID would depend on the
toxicity, route of administration, duration of the analgesia,
and cost. Therefore, we elected to use ketoprofen due to
its availability and its routine use at our institution. Con-
cerns have been raised regarding the potential side effects
Figure 2. Mean and standard deviation of the shoulder pain
scores in the different groups over time.
Table 2.
Number and Percentage of Patients Who Needed
Postoperative Rescue Analgesics
Group 1 Group 2 Group 3 Group 4 Group 5
13/20 10/20 8/20* 12/20 17/20
65% 50% 40%* 60% 85%
*P0.05 compared with group 5.
Table 3.
Number and Percentage of Patients Who Vomited
Group 1 Group 2 Group 3 Group 4 Group 5
5/20 8/20 3/20* 7/20 9/20
25% 40% 15%* 35% 45%
*P0.05 compared to group 5.
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ing, impaired coagulation, and renal dysfunction. How-
ever, the short-term use (48 hr to72 hr) of appropriate
dosages of NSAIDs appears to be safe and well tolerated
in patients undergoing ambulatory surgery.
Previous studies7 have shown that the intravenous admin-
istration of the nonsteroidal anti-inflammatory drug
tenoxicam failed to produce adequate analgesia following
laparoscopic surgery. In our study, intravenous ketopro-
fen was effective in significantly reducing shoulder pain at
0, 1, and 6 hours postoperatively; however, it was effec-
tive in decreasing postoperative abdominal pain at 2
hours only. Also, no significant difference occurred in the
number of patients who needed rescue analgesics or in
the incidence of postoperative vomiting as compared with
that in the control group.
The multimodal approach for pain management following
laparoscopic cholecystectomy has been previously shown
to be advantageous. Elhakim et al6 showed that a combi-
nation of intraperitoneal lidocaine and tenoxicam was
more effective in reducing pain scores and opioid con-
sumption than either placebo or intraperitoneal lidocaine
and intravenous tenoxicam, with no difference in the
incidence of nausea between the groups. In our study, a
combination of intraperitoneal bupivacaine and ketopro-
fen was effective in relieving postoperative abdominal
pain at 0, 1, 2, and 6 hours. It was also effective against
shoulder pain at 0 and 6 hours postoperatively. However,
it did not relieve abdominal pain at 12 hours and 24 hours.
Also, it did not provide a significant decrease in the num-
ber of patients who needed postoperative rescue analge-
sics, and it did not decrease the incidence of postoperative
vomiting as compared with vomiting in the control group.
The present report shows that the best technique for pain
relief following laparoscopic cholecystectomy is the mul-
timodal approach using a combination of intraperitoneal
bupivacaine and intravenous ketoprofen. This combina-
tion does not merely create an additive response but
rather a synergistic one through its action at 2 different
sites by 2 different mechanisms. While intraperitoneal
bupivacaine alone results in abdominal pain relief at 6
hours only, and intravenous ketoprofen alone results in
abdominal pain relief at 2 hours only, a combination of
intraperitoneal bupivacaine and intravenous ketoprofen
results in a significant decrease in abdominal pain scores
at 0, 1, 2, 6, 12, and 24 hours postoperatively. Also, it has
proven effective in relieving postoperative shoulder pain
at 0 and 6 hours with a significantly lower number of
patients who needed rescue analgesics and a significantly
lower incidence of postoperative vomiting.
CONCLUSION
Our study shows that the multimodal approach to pain
management following laparoscopic cholecystectomy is
best achieved with a combination of intraperitoneal spray
of 40 mL of bupivacaine 0.25% as a local anesthetic and
200 mg of intravenous ketoprofen as a nonsteroidal anti-
inflammatory drug. This combination of 2 drugs acting on
2 different sites by 2 different mechanisms results in a
synergistic action that significantly decreases postopera-
tive abdominal and shoulder pain. Also, it decreases the
number of patients who require postoperative rescue an-
algesics, as well as the incidence of postoperative vomit-
ing.
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